Article

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03

2024-08-11

Abstract excerpt

<h4>Background</h4> We report extended follow-up of TROG99.03, a randomised phase III trial in early-stage follicular lymphoma (ESFL) including new information on the role of adjuvant rituximab and translational studies. <h4>Methods</h4> Patients with ESFL were randomised to involved-field radiotherapy (IFRT) or IFRT plus 6-cycles cyclophosphamide/vincristine/prednisolone (IFRT+CVP). From 2006 rituximab was added...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 55e51e94-2d22-509f-8a82-4e300edaae70
DOI: 10.1101/2024.08.09.24311704

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Adjuvant rituximab and elevated intratumoural CD8 expression are associated with sustained disease control after radiotherapy in early-stage follicular lymphoma: TROG99.03DOI 10.1101/2024.08.09.24311704Read

Clinical characteristics and molecular heterogeneity in Follicular lymphoma with extranodal involvement.Semantic proximity Read

Patient-derived follicular lymphoma spheroids recapitulate lymph node signaling and immune profile uncovering galectin-9 as a novel immunotherapeutic targetSemantic proximity Read

Follicular lymphoma: are we ready for a risk-adapted approach?Semantic proximity Read

Current prognostic and predictive factors in follicular lymphoma.Semantic proximity Read

Decreased Expression of T-Cell-Associated Immune Markers Predicts Poor Prognosis in Patients with Advanced Follicular Lymphoma Received Rituximab Plus BendamustineSemantic proximity Read

Boosting γδ T cell-mediated antibody-dependent cellular cytotoxicity by PD-1 blockade in follicular lymphomaSemantic proximity Read

PD-1 expression defines two distinct T-cell sub-populations in follicular lymphoma that differentially impact patient survivalSemantic proximity Read

Decreased expression of T-cell-associated immune markers predicts poor prognosis in patients with follicular lymphoma.Semantic proximity Read

Spatial Proteomics Reveals Dual-Compartment Immune Evasion Architecture and Core Lymphomagenic Stromal Niches in Follicular LymphomaSemantic proximity Read

Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.Semantic proximity Read

Revealing the Evolution of the Tumor Immune Microenvironment in Follicular Lymphoma Patients Progressing Within 24 Months Using Single-cell Imaging Mass CytometrySemantic proximity Read

Epidemiology of Follicular Lymphoma.Semantic proximity Read